Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study.
Avcı O, İriağaç Y, Çavdar E, Karaboyun K, Araz M, Şakalar T, Değerli E, Özdemir Ö, İnal A, Ocak B, Ürün M, Sakin A, Yıldız Tacar S, Koçak MZ, Demir H, Özer Ö, Tanrıkulu Şimşek E, Ersoy M, Karakaş Y, Arıkan R, Eşbah O, Ön S, Şenocak Taşçı E, Molinas Mandel N, Türker S, Kaçan T, Yıldırım HÇ, Alan Ö, Akbaş S, İpek Deniz G, Aydın İsak Ö, Taşkaynatan H, Şeber ES. Avcı O, et al. Among authors: inal a. J Geriatr Oncol. 2023 Nov;14(8):101604. doi: 10.1016/j.jgo.2023.101604. Epub 2023 Sep 6. J Geriatr Oncol. 2023. PMID: 37683369
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ, Oyan B, Sönmez Ö, Mutlu AU, Atcı MM, Sakin A, Öner İ, Çınkır HY, Eryılmaz MK, Çağlayan D, Balçık OY, Paksoy N, Karabulut S, Salim DK, Bilir C, Özen M, Özçelik M, Arıcan A, Akagündüz B, İnal A, Aydın D, Özer L, Gülmez A, Turhal NS, Esen SA, Algın E, Akbaş S, İriağaç Y, Şakalar T, Ünal Ç, Er Ö, Seçmeler Ş, Bozkurt M. Taşçı EŞ, et al. Among authors: inal a. BMC Cancer. 2024 Jan 23;24(1):114. doi: 10.1186/s12885-024-11863-0. BMC Cancer. 2024. PMID: 38262962 Free PMC article. No abstract available.
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.
Kahraman S, Hizal M, Demirel BC, Guven DC, Gumusay O, Uluc BO, Bayram E, Gulbagci B, Yasar A, Davarci SE, Mocan EE, Acar O, Isik D, Aydin E, Karakas Y, Ozcelik M, Keser M, Okutur SK, Eren O, Menekse S, Aydin D, Yilmaz F, Dogan O, Ozkanli G, Yucel H, Sunar V, Aykan MB, Ozdemir O, Duman BB, Keskinkilic M, Sakalar T, Inal A, Karaoglanoglu M, Aksoy A, Er MM, Turhal NS, Kalkan NO, Sendur MAN. Kahraman S, et al. Among authors: inal a. BMC Cancer. 2024 Dec 30;24(1):1592. doi: 10.1186/s12885-024-13357-5. BMC Cancer. 2024. PMID: 39736618 Free PMC article.
Proteomic profiling reveals CEACAM6 function in driving gallbladder cancer aggressiveness through integrin receptor, PRKCD and AKT/ERK signaling.
Sugiyanto RN, Metzger C, Inal A, Truckenmueller F, Gür K, Eiteneuer E, Huth T, Fraas A, Heinze I, Kirkpatrick J, Sticht C, Albrecht T, Goeppert B, Poth T, Pusch S, Mehrabi A, Schirmacher P, Ji J, Ori A, Roessler S. Sugiyanto RN, et al. Among authors: inal a. Cell Death Dis. 2024 Oct 28;15(10):780. doi: 10.1038/s41419-024-07171-x. Cell Death Dis. 2024. PMID: 39468006 Free PMC article.
225 results